Avid Bioservices, Inc. (CDMO)
$
12.49
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avid Bioservices, Inc., a contract development and manufacturing organization, is focused on the biopharmaceutical industry, particularly in the production of drug substances derived from mammalian cell cultures, including monoclonal antibodies and recombinant proteins. The operating income ratio is -0.13 indicating the company's operational profitability margin. Despite its focus on providing CGMP clinical and commercial drug substance manufacturing, along with additional services such as bulk packaging, release and stability testing, and regulatory submission and support, the company reported a net loss of -$140,753,000.00 indicating challenges in its operations. The operating expenses amount to $25,996,000.00 encompassing various operational costs incurred in maintaining its services. Furthermore, the weighted average number of diluted shares outstanding is 63,199,000.00 reflecting potential dilution effects that could impact shareholders. The EBITDA is -$11,481,000.00 a key indicator of the company's operational profitability, showcasing its financial health in the biopharmaceutical landscape. In terms of market presence, the stock is affordable at $12.49 suitable for budget-conscious investors looking to enter this sector. The stock has a high average trading volume of 1,584,407.00 indicating strong liquidity, which may provide investors with confidence in the ease of trading shares. With a market capitalization of $798,901,617.00 the company is classified as a small-cap player, positioning it as a potentially agile competitor within its field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation. Avid Bioservices, Inc. belongs to the Healthcare sector, where it continues to foster growth and development, addressing the evolving needs of biotechnology and biopharmaceutical enterprises.
What is Avid Bioservices, Inc. (CDMO)'s stock forecast?
Analysts predict Avid Bioservices, Inc. stock to fluctuate between $5.90 (low) and $12.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avid Bioservices, Inc.'s market capitalization?
As of 2025-02-04, Avid Bioservices, Inc.'s market cap is $798,901,617, based on 63,963,300 outstanding shares.
How does Avid Bioservices, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Avid Bioservices, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Avid Bioservices, Inc. pay dividends?
Avid Bioservices, Inc. pays dividends. The current dividend yield is 25.34%, with a payout of $0.66 per share.
How can I buy Avid Bioservices, Inc. (CDMO) stock?
To buy Avid Bioservices, Inc. (CDMO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CDMO. Place an order (Market, Limit, etc.).
What is the best time to invest in Avid Bioservices, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Avid Bioservices, Inc. stock ever split?
Avid Bioservices, Inc.'s last stock split was 1:7 on 2017-07-10.
How did Avid Bioservices, Inc. perform in the last earnings report?
Revenue: $139,911,000 | EPS: -$2.23 | Growth: -24,877.78%.
Where can I find Avid Bioservices, Inc.'s investor relations reports?
Visit https://www.avidbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avid Bioservices, Inc.?
You can explore historical data from here
What is the all-time high and low for Avid Bioservices, Inc. stock?
All-time high: $34.51 (2021-11-11) | All-time low: $2.24 (2018-02-15).
What are the key trends affecting Avid Bioservices, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
10 days ago
SHANGHAI , March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.
prnewswire.com
17 days ago
JERUSALEM , March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be meeting with investors, showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO boutique services at the BIO-Europe Spring 2025 conference, taking place March 17-19 in Milan, Italy.
globenewswire.com
17 days ago
Humanetics' Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM)
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
a month ago
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
accessnewswire.com
2 months ago
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
See all news
